References

1. Denny L (2012) Cervical cancer prevention: new opportunities for primary and secondary prevention in the 21st century. Int J Gynaecol Obstet 119 Suppl 1: S80-84 [CrossRef] [Google Scholar] [PubMed]
2. Garnett GP, Kim JJ, French K, Goldie SJ (2006) Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 24 Suppl 3: S3/178-186 [CrossRef] [Google Scholar] [PubMed]
3. Massad LS, Einstein M, Myers E, Wheeler CM, Wentzensen N, et al. (2009) The impact of human papillomavirus vaccination on cervical cancer prevention efforts. Gynecol Oncol 114: 360-364 [CrossRef] [Google Scholar] [PubMed]
4. Lees BF, Erickson BK, Huh WK (2016) Cervical cancer screening: evidence behind the guidelines. Am J Obstet Gynecol 214: 438-443 [CrossRef] [Google Scholar] [PubMed]
5. Katki H, Schiffman M, Castle P, Fetterman B, Poitras N, et al. (2013) Fiveyear risk of CIN 3+ to guide the management of women aged 21 to 24 years. J Low Genit Tract Dis 17: S64-S68 [CrossRef] [PubMed]
6. Sigurdsson K (2010) Cervical cancer: cytological cervical screening in Iceland and implications of HPV vaccines. Cytopathology 21: 213-222 [CrossRef] [Google Scholar] [PubMed]
7. Sasieni P, Adams J, Cuzick J (2003) Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 89: 88-93 [CrossRef] [Google Scholar] [PubMed]
8. Stanley M (2008) Human papillomavirus vaccines versus cervical cancer screening. Clin Oncol (R Coll Radiol) 20: 388-394 [CrossRef] [Google Scholar] [PubMed]
9. Herbert A, Holdsworth G, Kubba AA (2008) Cervical screening: why young women should be encouraged to be screened. J Fam Plann Reprod Health Care 34: 21-25 [CrossRef] [Google Scholar] [PubMed]
10. Sopina E, Ashton T (2011) Cost-effectiveness of a cervical screening program with human papillomavirus vaccine. Int J Technol Assess Health Care 27: 290-297 [CrossRef] [Google Scholar] [PubMed]
11. Bosch X, Harper D (2006) Prevention strategies of cervical cancer in the HPV vaccine era. Gynecol Oncol 103: 21-24 [CrossRef] [Google Scholar] [PubMed]
12. Lynge E, Antilla A, Arbyn M, Segnan N, Ronco G (2009) What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination. Eur J Cancer 45: 2714-2721 [CrossRef] [Google Scholar] [PubMed]
13. Almonte M, Sasieni P, Cuzick J (2011) Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines. Best Pract Res Clin Obstet Gynaecol 25: 617-29 [CrossRef] [Google Scholar] [PubMed]
14. Bosch FX, Robles C, Díaz M, Arbyn M, Baussano I, et al. (2016) HPVFASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol 13: 119-132 [CrossRef] [Google Scholar] [PubMed]
15. Jeronimo J, Bansil P, Valdez M, Kang L, Zhao F, et al. (2015) The Influence of Human Papillomavirus Genotypes on Visual Screening and Diagnosis of Cervical Precancer and Cancer. J Low Genit Tract Dis 19: 220-223 [CrossRef] [Google Scholar] [PubMed]
16. Huh W, Ault K, Chelmow D, Davey D, Goulart R, et al. (2015) Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol 125: 330-337 [CrossRef] [Google Scholar] [PubMed]
17. El-Zein M, Richardson L, Franco EL (2016) Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none. J Clin Virol 76 Suppl 1: S62-68 [CrossRef] [Google Scholar] [PubMed]
18. Herweijer E, Feldman A, Ploner A, Arnheim-Dahlstrom L, Uhnoo I, et al. (2015) The Participation of HPV-Vaccinated Women in a National Cervical Screening Program: Population-Based Cohort Study. PLoS One 10: e0134185 [CrossRef] [Google Scholar] [PubMed]
19. Paynter C, Van Treeck B, Verdenius I, Lau A, Dhawan T, et al. (2015) Adherence to cervical cancer screening varies by human papillomavirus vaccination status in a high-risk population. Prev Med Rep 2: 711-716 [CrossRef] [Google Scholar] [PubMed]